% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Herrmann:132816,
author = {W. J. Herrmann and C. Weikert and M. Bergmann and H. Boeing
and V. Katzke$^*$ and R. Kaaks$^*$ and D. Tiller and K. H.
Greiser and M. Heier and C. Meisinger and C. O. Schmidt and
H. Neuhauser and C. Heidemann and C. Jünger and P. S. Wild
and S. H. Schramm and K.-H. Jöckel and M. Dörr and T.
Pischon},
title = {[{A}ssessing incident cardiovascular and metabolic diseases
in epidemiological cohort studies in {G}ermany].},
journal = {Bundesgesundheitsblatt, Gesundheitsforschung,
Gesundheitsschutz},
volume = {61},
number = {4},
issn = {1437-1588},
address = {Berlin},
publisher = {Springer},
reportid = {DKFZ-2018-00460},
pages = {420 - 431},
year = {2018},
abstract = {Cardiovascular and metabolic diseases are a major cause of
mortality and loss of quality of life in Germany. Research
into risk factors of these diseases requires large
population-based cohort studies. Complete and accurate
assessment of the incidence of cardiovascular and metabolic
diseases is a key element for valid interpretation of the
results from such studies.Our aim was to identify
population-based cohort studies with incidence of
cardiovascular and metabolic diseases in Germany and to
summarize their methods for assessment and classification of
disease endpoints, including myocardial infarction, type 2
diabetes, stroke, heart failure, and arterial
hypertension.Within the framework of a workshop,
representatives of the ascertained population-based cohort
studies in Germany with incidence of cardiovascular or
metabolic diseases were invited to present and to
systematically provide information on their methods of
endpoint identification.We identified eight studies from
different regions in Germany with a total of 100,571
participants, aged 18-83 years at baseline. Self-reporting
by study participants is the major source for further
inquiries to assess disease endpoints in these studies. Most
studies use additional data sources to verify the incidence
of diseases, such as documents provided by the treating
physician or hospital.Our results highlight the central role
of self-reporting and the efforts associated with
identification and verification of disease endpoints in
cohort studies. They also provide a basis for future
population-based studies that aim for standardized
assessment of the incidence of cardiovascular and metabolic
diseases.},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {323 - Metabolic Dysfunction as Risk Factor (POF3-323)},
pid = {G:(DE-HGF)POF3-323},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29487975},
doi = {10.1007/s00103-018-2712-4},
url = {https://inrepo02.dkfz.de/record/132816},
}